4-[-2-[[5-methyl-1-(2-naphtalenyl)-1Hpyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates

Details for Australian Patent Application No. 2011212476 (hide)

Owner LABORATORIOS DEL DR. ESTEVE, S.A.

Inventors Berenguer Maimo, Ramon; Medrano Ruperez, Jorge; Benet Buchholz, Jordi; Puig Fernandez, Laura; Pelleja Puxeu, Laia

Agent Collison & Co

Pub. Number AU-A-2011212476

PCT Pub. Number WO2011/095579

Priority 10382025.4 04.02.10 EP; 10382226.8 09.08.10 EP

Filing date 4 February 2011

Wipo publication date 11 August 2011

International Classifications

C07D 231/22 Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings

A61K 9/16 Medicinal preparations characterised by special physical form - Agglomerates

A61K 31/4152 - having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone

A61P 25/00 Drugs for disorders of the nervous system

Event Publications

9 August 2012 PCT application entered the National Phase

  PCT publication WO2011/095579 Priority application(s): WO2011/095579

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2011212477-F18-tyrosine derivatives for imaging bone metastases

2011212466-Phthalate-free isocyanurate formulations